Evolocumab Patent Exclusivity and Biosimilar Competition
Evolocumab, a cholesterol-lowering injection medication, is marketed by Amgen as Repatha. Developed in collaboration with Sanofi, evolocumab targets and reduces LDL (bad) cholesterol levels in the blood.
When Does Exclusivity Expire?
The evolocumab patent, as listed on DrugPatentWatch.com, is set to expire in the United States on January 5, 2036 (US Patent 8,536,164). However, patent extensions, regulatory exclusivities, and market changes may extend or impact exclusivity.
Biosimilar Challenges and Patent Litigation
Amgen and Sanofi have faced patent litigation and challenges to evolocumab from biosimilar manufacturers. Biosimilars, like those manufactured by Mylan and Sandoz, aim to replicate evolocumab's effects at a lower cost.
Current Patent Status and Exclusivity in Major Markets
According to DrugPatentWatch.com [1], evolocumab's patent status varies across major markets:
* United States: expires on January 5, 2036 (US Patent 8,536,164)
* European Union: expires on May 3, 2033 (EP 2451421 B1)
* Japan: expires on July 14, 2034 (JP 5901518 B2)
Regulatory Exclusivity and Market Impact
Regulatory exclusivities beyond patent expiration, such as orphan drug exclusivity, may extend market exclusivity. Additionally, evolocumab's market dominance and regulatory approvals have contributed to a high barrier for biosimilars to enter the market.
Pricing and Competition Landscape
Amgen's Repatha has a high list price for patients, which might change as biosimilars enter the market. However, patient access, reimbursement, and insurance coverage play a significant role in shaping the market dynamics.
Sources
[1] DrugPatentWatch.com. (n.d.). Repatha (Evolocumab) Patents. Retrieved from https://www.drugpatentwatch.com/patent/US-8536164/